The Role of Heat Shock Proteins in Mammary Neoplasms: A Brief Review

Research into heat shock proteins (HSPs) for the clinical management of tumours has intensified as new evidence shows they can be used as biomarkers in carcinogenesis and are related to poor prognosis in some cancer types. Members of small HSP, HSP70 and HSP90 families have been studied extensively in breast cancer. This article reviews current understanding of the role of HSP and HSF-1 (Heat shock factor 1) expression in human breast cancer and looks at its potential diagnostic, prognostic and therapeutic value. The exciting progress that has been made using HSP 90 inhibitors in breast cancer treatment is examined and the results of preliminary studies on the expression of stress proteins in the animal model canine mammary tumours are also presented.

• Publication year

  2012

• Venue

  Journal of Cancer Therapy

• Publication date

  2012-10-31

• Fields of study

  Medicine

• Identifiers
  DOI 10.4236/JCT.2012.325095
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Molecular chaperones in mammary cancer growth and breast tumor therapy

  2012cited by this paper
• Heat shock proteins in breast cancer progression–A suitable case for treatment?

  2010cited by this paper
• Geldanamycin and its anti-cancer activities.

  2010cited by this paper
• Hsp90 in the continuum of breast ductal carcinogenesis: Evaluation in precursors, preinvasive and ductal carcinoma lesions

  2010cited by this paper
• Heat shock transcription factor HSF1 plays a critical role in HER2-induced cellular transformation and tumorigenesis

  2010cited by this paper
• CEA-, Her2/neu-, BCRP- and Hsp27-positive microparticles in breast cancer patients.

  2010cited by this paper
• [Hoxa5: a master gene with multifaceted roles].

  2009cited by this paper
• New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential.

  2009cited by this paper
• Trithorax requires Hsp90 for maintenance of active chromatin at sites of gene expression

  2009cited by this paper
• Molecular chaperones in the etiology and therapy of cancer

  2008cited by this paper
• Silencing of HSP90 cochaperone AHA1 expression decreases client protein activation and increases cellular sensitivity to the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin.

  2008cited by this paper
• Development and application of Hsp90 inhibitors.

  2008cited by this paper
• Mechanisms Driving Local Breast Cancer Recurrence in a Model of Breast-Conserving Surgery

  2008cited by this paper
• Targeted therapies in breast cancer: where are we now?

  2008cited by this paper
• Recent advances in Hsp90 inhibitors as antitumor agents.

  2008cited by this paper
• Heat-shock proteins in cancer vaccines: agents of antigen cross-presentation

  2008cited by this paper
• A Phase I Study of 17-Allylamino-17-Demethoxygeldanamycin Combined with Paclitaxel in Patients with Advanced Solid Malignancies

  2008cited by this paper
• A novel class of small molecule inhibitors of Hsp90.

  2008cited by this paper
• P-Cadherin and β-catenin are useful prognostic markers in breast cancer patients; β-catenin interacts with heat shock protein Hsp27

  2008cited by this paper
• Targeting Hsp90 prevents escape of breast cancer cells from tyrosine kinase inhibition

  2008cited by this paper
• A small molecule cell-impermeant Hsp90 antagonist inhibits tumor cell motility and invasion

  2008cited by this paper
• Guidelines for the nomenclature of the human heat shock proteins

  2008cited by this paper
• Heat shock proteins in animal neoplasms and human tumours—a comparison

  2008cited by this paper
• NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models

  2008cited by this paper
• Spontaneous Mammary Intraepithelial Lesions in Dogs—A Model of Breast Cancer

  2007cited by this paper
• Diverse cellular functions of the Hsp90 molecular chaperone uncovered using systems approaches.

  2007cited by this paper
• Next generation molecular targeted agents for breast cancer: focus on EGFR and VEGFR pathways

  2007cited by this paper
• Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.

  2007cited by this paper
• Intracellular and extracellular functions of heat shock proteins: repercussions in cancer therapy

  2007cited by this paper
• Hydroxamic Acid Analogue Histone Deacetylase Inhibitors Attenuate Estrogen Receptor-α Levels and Transcriptional Activity: A Result of Hyperacetylation and Inhibition of Chaperone Function of Heat Shock Protein 90

  2007cited by this paper
• Extracellular heat shock protein 90: A role for a molecular chaperone in cell motility and cancer metastasis

  2007cited by this paper
• High HSP90 expression is associated with decreased survival in breast cancer.

  2007cited by this paper
• Hsp-based tumor vaccines: state-of-the-art and future directions.

  2007cited by this paper
• Survivin, a member of the inhibitor of apoptosis family, is induced by photodynamic therapy and is a target for improving treatment response.

  2007cited by this paper
• Chemotherapy: induction of stress responses.

  2006cited by this paper
• Inhibition of Hsp90 acts synergistically with topoisomerase II poisons to increase the apoptotic killing of cells due to an increase in topoisomerase II mediated DNA damage

  2006cited by this paper
• A biochemical rationale for the anticancer effects of Hsp90 inhibitors: Slow, tight binding inhibition by geldanamycin and its analogues

  2006cited by this paper
• Of humans and canines: a comparative evaluation of heat shock and apoptosis-associated proteins in mammary tumors.

  2006cited by this paper
• Improved efficacy of DNA vaccination against breast cancer by boosting with the repeat beta-hCG C-terminal peptide carried by mycobacterial heat-shock protein HSP65.

  2006cited by this paper
• Cooperative inhibitory effect of ZD1839 (Iressa) in combination with 17‐AAG on glioma cell growth

  2006cited by this paper
• Schedule-Dependent Synergy between the Heat Shock Protein 90 Inhibitor 17-(Dimethylaminoethylamino)-17-Demethoxygeldanamycin and Doxorubicin Restores Apoptosis to p53-Mutant Lymphoma Cell Lines

  2006cited by this paper
• A Phase I Trial of Twice-Weekly 17-Allylamino-Demethoxy-Geldanamycin in Patients with Advanced Cancer

  2006cited by this paper
• Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.

  2006cited by this paper
• Heat shock protein-based cancer vaccines.

  2006cited by this paper
• Effectiveness of hsp90 inhibitors as anti-cancer drugs.

  2006cited by this paper
• Breast cancer metastasis suppressor 1 (BRMS1) is stabilized by the Hsp90 chaperone.

  2006cited by this paper
• Distribution of hsp-27 and HER-2/neu in in situ and invasive ductal breast carcinomas

  2006cited by this paper
• Inducible heat shock protein 70 expression as a potential predictive marker of metastasis in breast tumors

  2006cited by this paper
• 17-dimethylaminoethylamino-17-demethoxygeldanamycin in patients with advanced-stage solid tumors and lymphoma: a phase I study.

  2006cited by this paper
• Heat shock proteins: endogenous modulators of apoptotic cell death.

  2006cited by this paper
• The distinctive role of small heat shock proteins in oncogenesis

  2006cited by this paper
• Heat shock protein expression in canine malignant mammary tumours

  2006cited by this paper
• Discovery and development of purine-scaffold Hsp90 inhibitors.

  2006cited by this paper
• Heat Shock Proteins 27 and 70: Anti-Apoptotic Proteins with Tumorigenic Properties

  2006cited by this paper
• Hsp90 inhibitors in the clinic.

  2006cited by this paper
• Inhibitors of the HSP90 molecular chaperone: current status.

  2006cited by this paper
• Co-expression of steroid receptors (estrogen receptor alpha and/or progesterone receptors) and Her-2/neu: Clinical implications.

  2006cited by this paper
• Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT

  2006cited by this paper
• Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine.

  2005cited by this paper
• Using a xenograft model of human breast cancer metastasis to find genes associated with clinically aggressive disease.

  2005cited by this paper
• Navigating the chaperone network: an integrative map of physical and genetic interactions mediated by the hsp90 chaperone.

  2005cited by this paper
• Heat-shock protein 90 inhibitors as novel cancer chemotherapeutics – an update

  2005cited by this paper
• 17-Allylamino-17-demethoxygeldanamycin overcomes TRAIL resistance in colon cancer cell lines.

  2005cited by this paper
• Phase I Pharmacokinetic-Pharmacodynamic Study of 17-(Allylamino)-17-Demethoxygeldanamycin (17AAG, NSC 330507), a Novel Inhibitor of Heat Shock Protein 90, in Patients with Refractory Advanced Cancers

  2005cited by this paper
• Aberrant expression of HOX genes in human invasive breast carcinoma.

  2005cited by this paper
• Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.

  2005cited by this paper
• Death versus survival: functional interaction between the apoptotic and stress-inducible heat shock protein pathways.

  2005cited by this paper
• Blocking Tumor Cell Migration and Invasion with Biphenyl Isoxazole Derivative KRIBB3, a Synthetic Molecule That Inhibits Hsp27 Phosphorylation*

  2005cited by this paper
• Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications

  2005cited by this paper
• Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies.

  2005cited by this paper
• Silencing the hsp25 Gene Eliminates Migration Capability of the Highly Metastatic Murine 4T1 Breast Adenocarcinoma Cell

  2005cited by this paper
• Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors.

  2005cited by this paper
• Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer.

  2005cited by this paper
• Heat shock protein 27 is associated with decreased survival in node-negative breast cancer patients.

  2005cited by this paper
• Heat shock proteins as emerging therapeutic targets

  2005cited by this paper
• The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line.

  2005cited by this paper
• Surface Expression of Hsp25 and Hsp72 Differentially Regulates Tumor Growth and Metastasis

  2004cited by this paper
• Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone.

  2004cited by this paper
• Cotreatment with 17-Allylamino-Demethoxygeldanamycin and FLT-3 Kinase Inhibitor PKC412 Is Highly Effective against Human Acute Myelogenous Leukemia Cells with Mutant FLT-3

  2004cited by this paper
• Altered Hsp90 function in cancer: a unique therapeutic opportunity.

  2004cited by this paper
• Antiangiogenic Properties of 17-(Dimethylaminoethylamino)-17-Demethoxygeldanamycin

  2004cited by this paper
• Heat shock proteins and drug resistance

  2004cited by this paper
• Increased risk of malignant progression in benign proliferating breast lesions defined by expression of heat shock protein 27

  2004cited by this paper
• αB‐crystallin as a marker of lymph node involvement in breast carcinoma

  2004cited by this paper
• Hsp90: an emerging target for breast cancer therapy

  2004cited by this paper
• Relationship between 90-kilodalton heat shock protein, estrogen receptor, and progesterone receptor in human mammary tumors

  2004cited by this paper
• Overexpression of the glucose-regulated stress gene GRP78 in malignant but not benign human breast lesions

  2004cited by this paper
• Prognostic significance of heat-shock protein-27 in node-positive breast carcinoma: an immunohistochemical study

  2004cited by this paper
• Role of BRCA1 in heat shock response

  2003cited by this paper
• The C-terminal half of heat shock protein 90 represents a second site for pharmacologic intervention in chaperone function.

  2003cited by this paper
• A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors

  2003cited by this paper
• Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer.

  2003cited by this paper
• Coadministration of the heat shock protein 90 antagonist 17-allylamino- 17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells.

  2003cited by this paper
• Heat-shock protein 70 as a prognostic marker in node-negative breast cancer.

  2003cited by this paper
• Clinicopathological study of the expression of hsp27, pS2, cathepsin D and metallothionein in primary invasive breast cancer.

  2003cited by this paper
• Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses.

  2002cited by this paper
• BAG‐1 expression in human breast cancer: interrelationship between BAG‐1 RNA, protein, HSC70 expression and clinico‐pathological data

  2002cited by this paper
• Hsp27 as a Negative Regulator of Cytochrome c Release

  2002cited by this paper
• Genetic variation in the tumor necrosis factor-alpha promoter region and in the stress protein hsp70-2: susceptibility and prognostic implications in breast carcinoma.

  2001cited by this paper
• Hsp90: a specialized but essential protein-folding tool.

  2001cited by this paper

• Circulating level of heat shock protein 27 is elevated in dogs with mammary tumors

  2019cites this paper
• The overexpression of Hsp90B1 is associated with tumorigenesis of canine mammary glands

  2018cites this paper
• Heat Shock Protein Expression and Implications in Spontaneous Animal Tumors: Veterinary and Comparative Aspects

  2017cites this paper
• Immunohistochemical evaluation of heat shock protein expression in normal canine nerve and peripheral nerve sheath tumours.

  2013cites this paper